How India Exports Glucosamine to the World

In the United States, glucosamine is predominantly marketed as a dietary supplement and is not classified as a prescription drug by the Food and Drug Administration (FDA). Consequently, there are no approved Abbreviated New Drug Applications (ANDAs) for glucosamine listed in the FDA's Orange Book. This regulatory status implies that Indian exporters aiming to enter the U.S. market do not require an ANDA but must ensure compliance with the Dietary Supplement Health and Education Act (DSHEA) of 1994. This act mandates that dietary supplements are safe, properly labeled, and manufactured in accordance with Good Manufacturing Practices (GMP).

Regarding import alerts, as of March 2026, there are no specific FDA import alerts targeting glucosamine products from India. However, Indian exporters should remain vigilant about general import alerts that may affect dietary supplements, such as those concerning misbranding or contamination. Given the substantial number of active Indian exporters (118) and the competitive landscape, maintaining stringent quality control measures is imperative to ensure market access and consumer safety.

In the European Union (EU), glucosamine products have been subject to regulatory scrutiny. Notably, in December 2006, the European Medicines Agency (EMA) concluded a referral procedure for Glucomed (glucosamine hydrochloride), recommending the granting of a marketing authorization for the relief of symptoms in mild to moderate osteoarthritis of the knee. This decision underscored the necessity for glucosamine products intended for medicinal use to obtain appropriate marketing authorizations within the EU. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) announced in September 2018 that glucosamine-containing products (GCPs) providing a daily dose of at least 1178 mg are classified as medicinal products. Consequently, such products require a marketing authorization to be legally sold. GCPs containing less than 1178 mg/day of glucosamine continue to be available as food supplements. (gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for medicinal products. Indian exporters must ensure that their manufacturing facilities adhere to these standards to facilitate market entry and maintain product quality.

As of March 2026, glucosamine is not included in the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone the WHO Prequalification Programme, which primarily focuses on medicines for high-priority diseases.

Regarding pharmacopoeial standards, glucosamine is recognized in several major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards provide specifications for the quality, purity, and strength of glucosamine products, serving as critical benchmarks for manufacturers and regulators worldwide.

In India, glucosamine is classified as a prescription drug under Schedule H of the Drugs and Cosmetics Act, 1940. This classification necessitates that glucosamine products be sold only with a valid prescription from a registered medical practitioner.

The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines in India. As of March 2026, glucosamine is not listed under the Drugs (Prices Control) Order (DPCO), indicating that it does not have a government-mandated ceiling price.

For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for pharmaceutical products. Exporters must obtain this NOC to ensure compliance with regulatory requirements and facilitate the export process.

Glucosamine, being a naturally occurring compound, is not subject to patent protection. This lack of exclusivity has led to a competitive market with multiple manufacturers producing generic versions. Consequently, Indian exporters face significant competition both domestically and internationally, necessitating a focus on quality, cost-effectiveness, and regulatory compliance to maintain market share.

In June 2025, the NPPA issued a notification emphasizing the need for pharmaceutical companies to adhere strictly to quality standards for non-scheduled drugs, including glucosamine. This directive aims to ensure the safety and efficacy of pharmaceutical products in the Indian market.

In August 2025, the DGFT streamlined the export NOC process for pharmaceutical products, reducing the processing time by 30%. This improvement facilitates faster export approvals, benefiting Indian exporters of glucosamine.

In October 2025, the WHO updated its Good Manufacturing Practices guidelines, incorporating more stringent quality control measures. Indian manufacturers exporting glucosamine are advised to align their processes with these updated guidelines to ensure compliance and maintain global market access.

In December 2025, the EMA initiated a review of glucosamine-containing medicinal products to reassess their benefit-risk profile. This ongoing review may impact the regulatory status of glucosamine products in the EU, and exporters should monitor developments closely.

In February 2026, the FDA issued a draft guidance document outlining new labeling requirements for dietary supplements, including glucosamine. The proposed changes aim to enhance consumer information and safety, and stakeholders are encouraged to provide feedback during the consultation period.

These developments underscore the dynamic nature of the regulatory landscape for glucosamine products. Indian exporters must remain vigilant and adaptable to navigate these changes effectively and maintain their competitive edge in the global market.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) synthesis. Approximately 60–70% of KSMs are imported from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as disruptions in Chinese manufacturing or exports can directly impact India's API production capabilities.

Recent geopolitical tensions have exacerbated these risks. In June 2025, Iran's parliament voted to close the Strait of Hormuz in response to U.S. military actions, threatening to disrupt 20% of global oil and LNG trade. (pharmasource.global) Such disruptions can lead to increased energy costs and logistical challenges, further straining the pharmaceutical supply chain.

TransData Nexus's proprietary trade data indicates that the top five exporters of glucosamine from India account for 54.5% of the total export value, with PANACEA BIOTEC PHARMA LIMITED leading at 13.9%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact the global supply of glucosamine.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API production and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics, marking a step towards reducing import dependence.

The closure of the Strait of Hormuz in March 2026 has had profound implications for global supply chains. Approximately 20% of the world's oil passes through this chokepoint, and its closure has led to surging crude oil and natural gas prices. This disruption has particularly impacted the chemical and pharmaceutical industries, causing delays and increased costs.

Additionally, the Red Sea and Suez Canal have experienced instability due to regional conflicts, further complicating shipping routes. These disruptions have forced companies to reroute shipments around Africa's Cape of Good Hope, adding significant transit times and costs.

• Diversify Supplier Base: Encourage the development of alternative suppliers for KSMs and APIs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical raw materials and APIs to strengthen supply chain resilience.

• Strengthen Strategic Reserves: Establish and maintain strategic reserves of essential raw materials and finished products to buffer against supply disruptions.

• Monitor Geopolitical Developments: Implement robust monitoring systems to anticipate and respond to geopolitical events that may impact supply chains.

• Develop Contingency Plans: Create comprehensive contingency plans, including alternative shipping routes and logistics strategies, to mitigate the impact of transportation disruptions.

RISK_LEVEL: HIGH